Profile data is unavailable for this security.
About the company
Elekta publ AB is a Sweden-based human care company that develops and sells clinical solutions for the treatment of cancer and brain disorder. The Company offers and develops systems for radiation therapy and radio-surgery, as well as software systems that enhance workflow efficiency throughout the entire spectrum of cancer care. The Company has four product areas: Elekta Neuroscience, which develops solutions for the diagnosis and treatment of neurological diseases; Elekta Oncology, which creates clinical solutions for radiation therapy, such as linear accelerators, integrated imaging systems and clinical solutions for patient positioning and immobilization; Elekta Brachytherapy, which is engaged in the treatment of cancer through internal radiation, and Elekta Software, which develops software solutions for patient information, workflow management and treatment planning in oncology. The Company owns the service business of Asesores Electronicos Especializados SA de CV (AEESA).
- Revenue in SEK (TTM)18.22bn
- Net income in SEK1.43bn
- Incorporated1972
- Employees4.58k
- LocationElekta AB (publ)Kungstensgatan 18STOCKHOLM 113 57SwedenSWE
- Phone+46 858725400
- Fax+46 858725500
- Websitehttps://www.elekta.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenio Group Oyj | 1.13bn | 222.05m | 7.86bn | 216.00 | 35.00 | 6.71 | 29.32 | 6.96 | 0.7205 | 0.7205 | 3.66 | 3.76 | 0.7069 | 5.50 | 7.60 | 447,574.10 | 13.90 | 14.33 | 16.77 | 17.90 | 51.01 | 50.73 | 19.66 | 21.13 | 1.79 | 28.49 | 0.1521 | 55.81 | -0.4125 | 25.80 | -12.15 | 18.72 | 17.67 | 6.30 |
| Synsam AB (publ) | 5.91bn | 311.00m | 7.91bn | 3.41k | 25.25 | 3.11 | 7.49 | 1.34 | 2.09 | 2.09 | 39.62 | 16.96 | 0.7356 | 2.22 | 13.12 | 1,730,149.00 | 3.86 | -- | 5.27 | -- | 75.50 | -- | 5.25 | -- | 0.4922 | -- | 0.5675 | -- | 11.90 | -- | -5.18 | -- | -- | -- |
| Xvivo Perfusion AB | 597.54m | 91.82m | 11.75bn | 160.00 | 121.54 | 6.04 | 77.44 | 19.66 | 3.07 | 3.07 | 19.95 | 61.75 | 0.3042 | 1.23 | 6.20 | 3,734,638.00 | 4.67 | 1.23 | 5.02 | 1.33 | 74.49 | 73.14 | 15.37 | 4.76 | 5.09 | -- | 0.0159 | 0.00 | 43.88 | 26.04 | 398.29 | 48.57 | 21.35 | -- |
| Arjo AB (publ) | 11.10bn | 518.00m | 11.81bn | 6.71k | 24.43 | 1.56 | 7.62 | 1.06 | 1.90 | 1.90 | 40.76 | 29.72 | 0.6911 | 4.15 | 6.31 | 1,632,980.00 | 3.21 | 3.55 | 4.44 | 5.55 | 43.43 | 44.01 | 4.64 | 5.41 | 0.6913 | 4.14 | 0.4024 | 43.01 | 10.03 | 5.97 | 6.90 | 10.15 | -8.89 | 10.35 |
| Biotage AB | 1.98bn | 236.00m | 13.24bn | 669.00 | 54.97 | 3.40 | 32.86 | 6.68 | 3.01 | 3.01 | 25.57 | 48.61 | 0.5276 | 2.01 | 7.78 | 2,939,169.00 | 6.29 | 10.74 | 7.33 | 12.77 | 62.19 | 61.34 | 11.91 | 15.77 | 1.52 | 8.95 | 0.062 | 40.11 | 18.90 | 15.37 | -8.21 | 7.97 | 14.05 | 1.30 |
| Embla Medical hf | 8.78bn | 621.76m | 19.62bn | 4.00k | 31.48 | 2.45 | 16.62 | 2.23 | 0.9305 | 0.9305 | 13.13 | 11.94 | 0.5582 | 2.20 | 6.60 | 1,402,405.00 | 3.96 | 4.06 | 4.68 | 4.76 | 61.41 | 62.47 | 7.09 | 6.91 | 1.07 | 5.81 | 0.4325 | 3.99 | 9.33 | 5.09 | 37.34 | -6.05 | 6.50 | -- |
| Elekta AB (publ) | 18.22bn | 1.43bn | 27.87bn | 4.58k | 20.20 | 2.82 | 11.00 | 1.53 | 3.74 | 3.74 | 47.60 | 26.82 | 0.6208 | 3.29 | 2.90 | 4,150,570.00 | 4.89 | 4.32 | 8.69 | 7.89 | 37.90 | 39.93 | 7.88 | 7.68 | 0.8219 | 4.02 | 0.4106 | 65.79 | 15.95 | 7.83 | -18.28 | -6.90 | 12.86 | 11.38 |
| Ambu A/S | 7.67bn | 372.79m | 40.69bn | 4.70k | 122.65 | 5.43 | 43.73 | 5.30 | 0.9014 | 0.9014 | 18.71 | 20.36 | 0.7075 | 2.00 | 7.26 | 1,060,875.00 | 3.44 | 3.81 | 3.97 | 4.62 | 56.97 | 59.37 | 4.86 | 5.43 | 1.30 | 7.20 | 0.1038 | 22.89 | 7.45 | 12.88 | 80.65 | -13.00 | 6.67 | -- |
| GN Store Nord A/S | 28.38bn | 357.13m | 44.45bn | 7.17k | 122.82 | 2.86 | 14.23 | 1.57 | 1.53 | 1.53 | 130.43 | 65.84 | 0.5919 | 2.96 | 4.28 | 2,528,960.00 | 0.8688 | 4.91 | 1.57 | 7.44 | 49.55 | 53.29 | 1.47 | 6.82 | 0.4812 | 1.88 | 0.5847 | 36.84 | -3.03 | 11.30 | -55.38 | -28.74 | 7.53 | -- |
| Getinge AB | 32.20bn | 2.28bn | 59.75bn | 11.86k | 28.04 | 1.98 | 15.09 | 1.86 | 8.39 | 8.39 | 118.22 | 118.80 | 0.6001 | 2.53 | 6.79 | 2,742,908.00 | 4.29 | 5.31 | 5.56 | 6.98 | 45.37 | 47.83 | 7.15 | 8.69 | 0.7569 | 11.47 | 0.2035 | 37.87 | 12.49 | 5.66 | -3.17 | -- | -0.3944 | 34.49 |
| Demant A/S | 35.15bn | 4.00bn | 113.10bn | 21.62k | 28.56 | 7.78 | -- | 3.22 | 11.44 | 8.05 | 100.58 | 41.97 | 0.7431 | 2.05 | 5.88 | 1,037,923.00 | 8.46 | 8.27 | 12.20 | 13.23 | 73.72 | 74.14 | 11.38 | 11.34 | 0.9529 | 5.98 | 0.6075 | 0.00 | 13.89 | 10.00 | 12.23 | 6.96 | 8.80 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2023 | 34.76m | 9.43% |
| Nordea Investment Management ABas of 29 Feb 2024 | 14.55m | 3.95% |
| SEB Investment Management ABas of 28 Mar 2024 | 14.07m | 3.82% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 12.58m | 3.41% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 11.85m | 3.21% |
| Swedbank Robur Fonder ABas of 29 Feb 2024 | 11.73m | 3.18% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 11.15m | 3.03% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 8.55m | 2.32% |
| Didner & Gerge Fonder ABas of 31 Aug 2023 | 8.15m | 2.21% |
| Carnegie Fonder ABas of 28 Mar 2024 | 7.20m | 1.95% |
